TYRONE FILLYAW: Open Payments
NPI 1124285093 · CHEVY CHASE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$141 in 7 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $141
Food & beverage: $141
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Bausch Health US, LLC | 1 | $23 |
| Invivyd Inc | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
Products named: REXULTI, UZEDY, APLENZIN, PEMGARDA, COBENFY, NP Thyroid 60.
Industry payments across MD — which companies pay providers there.
